Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir
Authors
Keywords
-
Journal
Scientific Reports
Volume 10, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-10-06
DOI
10.1038/s41598-020-73641-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus
- (2020) Calvin J Gordon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
- (2020) Abdo A. Elfiky LIFE SCIENCES
- A Novel Coronavirus from Patients with Pneumonia in China, 2019
- (2020) Na Zhu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?
- (2020) Babak Sayad et al. ARCHIVES OF MEDICAL RESEARCH
- Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
- (2020) Calvin J. Gordon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- SARS-CoV-2 RNA polymerase as target for antiviral therapy
- (2020) Luigi Buonaguro et al. Journal of Translational Medicine
- Structure of replicating SARS-CoV-2 polymerase
- (2020) Hauke S. Hillen et al. NATURE
- Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19
- (2020) Richard T. Eastman et al. ACS Central Science
- A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19
- (2020) Steffen Jockusch et al. ANTIVIRAL RESEARCH
- Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites
- (2020) Ashleigh Shannon et al. ANTIVIRAL RESEARCH
- Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19
- (2020) Minchen Chien et al. JOURNAL OF PROTEOME RESEARCH
- Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic
- (2020) Rodrigo Jácome et al. Scientific Reports
- Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial
- (2020) Anahita Sadeghi et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Structural and Functional Basis of the Fidelity of Nucleotide Selection by Flavivirus RNA-Dependent RNA Polymerases
- (2018) Barbara Selisko et al. Viruses-Basel
- The ProTide Prodrug Technology: Where Next?
- (2018) Ashwag S. Alanazi et al. ACS Medicinal Chemistry Letters
- NS5A inhibitors for the treatment of hepatitis C infection
- (2017) Stefano Gitto et al. JOURNAL OF VIRAL HEPATITIS
- Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA
- (2017) François Ferron et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy
- (2016) L.B. Dustin et al. CLINICAL MICROBIOLOGY AND INFECTION
- Approved Antiviral Drugs over the Past 50 Years
- (2016) Erik De Clercq et al. CLINICAL MICROBIOLOGY REVIEWS
- Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C
- (2016) Polina German et al. CLINICAL PHARMACOKINETICS
- Coronaviruses — drug discovery and therapeutic options
- (2016) Alimuddin Zumla et al. NATURE REVIEWS DRUG DISCOVERY
- Daclatasvir
- (2015) Michael A. Smith et al. ANNALS OF PHARMACOTHERAPY
- Structural basis and functional analysis of the SARS coronavirus nsp14–nsp10 complex
- (2015) Yuanyuan Ma et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance
- (2015) Auda Eltahla et al. Viruses-Basel
- Common and unique features of viral RNA-dependent polymerases
- (2014) Aartjan J. W. te Velthuis CELLULAR AND MOLECULAR LIFE SCIENCES
- Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Jordan J. Feld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- RNA 3'-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex
- (2012) M. Bouvet et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Discovery of a β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus
- (2010) Michael J. Sofia et al. JOURNAL OF MEDICINAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More